


1644

THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Donald L.N. Cardy et al

Attorney Docket: 960670.CON

Serial No.: 08/737,457

Group Art Unit: 1644

Filed: March 12, 1997

Examiner: Ewoldt, Gerald R.

Int'l Application: PCT/GB95/01107

Paper: 20

Int'l Filing Date: May 15, 1995

F/H 20
MMT
9-20-00
RECEIVED

SEP 20 2000

TECH CENTER 1600/2900

For: IMPROVEMENTS IN OR RELATING TO PEPTIDE DELIVERY

RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action mailed June 13, 2000, please amend the application as follows:

REMARKS

This Amendment and Response is submitted in response to the Office Action mailed June 13, 2000. Claims 1 to 3, 5 to 12 and 14 to 24 have been rejected. Claims 1 to 3, 5 to 12 and 14 to 24 are pending.

Examiner states that Applicants have not complied with the requirements of 37 C.F.R. 1.821 through 1.825. Applicants will provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a substitute paper copy of the "Sequence Listing".

Examiner rejects Claims 1, 5 to 11, 13 and 20 to 23 under 35 U.S.C. § 102(b) as anticipated by U.S. Patent No. 5,283,323 (the '323 patent). Examiner states that the '323 patent teaches a chimeric polypeptide comprising an immunoglobulin molecule, which comprises a binding portion, and a translocation portion and an effector portion. Further, Examiner states that the '323 polypeptide